GlassScriptPhysician profile
Roxana M Stanescu
NPI 1861585945
$10,180.08
in general payments reported to CMS, 2019-2025
61 companies · $907 in 2025
The $907 reported for 2025 was more than what 83% of Internal Medicine providers received nationally (typical 2025 total: $156).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $1,685 · 2020: $939 · 2021: $1,467 · 2022: $1,789 · 2023: $1,914 · 2024: $1,480 · 2025: $907.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $4,301.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $4,300.59 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Novo Nordisk INC | $1,282.99 | 2019-2025 | Ozempic, Rybelsus, Wegovy |
| Amgen INC. | $1,077.43 | 2019-2025 | Evenity, Prolia, Otezla |
| Lilly USA, LLC | $931.16 | 2019-2025 | Mounjaro, Zepbound, Jardiance |
| Pfizer INC. | $894.50 | 2019-2025 | |
| Abbvie INC. | $693.46 | 2019-2025 | Synthroid |
| Abbott Laboratories | $495.67 | 2022-2025 | Freestyle Libre 3, Proclaim |
| Boehringer Ingelheim Pharmaceuticals, INC. | $459.69 | 2019-2024 | Jardiance, Tradjenta, Ofev |
| Astrazeneca Pharmaceuticals LP | $367.12 | 2019-2025 | Airsupra, Breztri |
| Merck Sharp & Dohme LLC | $344.24 | 2019-2025 | Gardasil 9, Capvaxive, Gardasil |
| Astellas Pharma US INC | $266.14 | 2019-2025 | Veozah, Myrbetriq |
| E.R. Squibb & Sons, L.L.C. | $239.91 | 2019-2025 | Eliquis |
| Novartis Pharmaceuticals Corporation | $220.12 | 2019-2024 | |
| Dexcom, INC. | $218.98 | 2022-2024 | Dexcom G6 Transmitter |
| Bayer Healthcare Pharmaceuticals INC. | $164.40 | 2022-2023 | |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $149.13 | 2019-2025 | Xifaxan |
Show all 61 companies
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Roxana Stanescu listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.